Department of Ophthalmology, Ankara University Faculty of Medicine, Mamak, Ankara, Turkey.
Ocul Immunol Inflamm. 2022 Jan 2;30(1):203-207. doi: 10.1080/09273948.2020.1774907. Epub 2020 Aug 11.
To evaluate the clinical course of patients with Behçet uveitis after discontinuation of infliximab (IFX) therapy.
Medical records of eight patients who discontinued treatment between 2010 and 2018 were retrospectively analyzed. The main outcome measures were frequency of uveitis attacks per year, best-corrected visual acuity (BCVA), aqueous flare, foveal thickness and fluorescein angiography (FA) scores before initiation, during treatment and after 6, 12, and 24 months of cessation of the IFX therapy.
The mean follow-up after withdrawal of infusions was 38.6 ± 20.4 (12-90) months. Frequency of uveitis attacks, BCVA, aqueous flare, foveal thickness and FA scores were improved significantly after treatment ( < .05). In terms of these parameters, there was no significant difference between the periods of during treatment and after 6, 12, and 24 months of cessation of the IFX therapy.
IFX therapy might be discontinued safely with an effective inflammation control in patients with Behçet uveitis.
评估贝赫切特葡萄膜炎患者停用英夫利昔单抗（IFX）治疗后的临床病程。
回顾性分析 2010 年至 2018 年期间停用治疗的 8 例患者的病历。主要观察指标为每年葡萄膜炎发作次数、最佳矫正视力（BCVA）、房水闪辉、黄斑中心凹厚度和荧光素血管造影（FA）评分，分别在起始治疗前、治疗期间以及停药后 6、12 和 24 个月进行评估。
停药后平均随访时间为 38.6±20.4（12-90）个月。治疗后葡萄膜炎发作次数、BCVA、房水闪辉、黄斑中心凹厚度和 FA 评分均显著改善（<0.05）。在这些参数方面，治疗期间与停药后 6、12 和 24 个月之间无显著差异。
对于贝赫切特葡萄膜炎患者，IFX 治疗可在有效控制炎症的情况下安全停药。
